ArticleJAMA network open2020
Association of Mortality and Years of Potential Life Lost With Active Tuberculosis in the United States.
Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Systematic review of the tuberculosis burden in prisons: Regional patterns and gaps in Latin America and the Caribbean.Global epidemiology · 2026Review
- The ghost of tuberculosis past.Nature medicine · 2026Article
- Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Predictors of excess length of stay among tuberculosis patients at Highland Hospital, Alameda County, California, 2018-2022.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Impact of tuberculosis on median survival time and years of potential life lost in patients: A scoping review.Journal of clinical tuberculosis and other mycobacterial diseases · 2025Review
- Analyzing the distribution of virulence factors ofVirulence · 2025Article
- Uptake and disparities in tuberculosis screening using urine-lipoarabinomannan among patients with advanced human immunodeficiency virus-disease in Africa: A systematic review.World journal of virology · 2025Article
- Implications of progressive lung damage and post-tuberculosis sequelae for the health benefits of prompt tuberculosis treatment in high HIV prevalence settings: a mathematical modelling analysis.The Lancet. Global health · 2025Article
- Contribution of Posttuberculosis Sequelae to Life-Years Lost from Tuberculosis Disease in the United States, 2015-2019.American journal of respiratory and critical care medicine · 2025Article
- Cycloserine-Induced Psychosis: A Case Report.Cureus · 2025Article
- Inclusion of patient-centered, non-microbiological endpoints and biomarkers in tuberculosis drug trials.Frontiers in antibiotics · 2025Review
- Mortality Rates after Tuberculosis Treatment, Georgia, USA, 2008-2019.Emerging infectious diseases · 2024Review
- Global burden of disease due to rifampicin-resistant tuberculosis: a mathematical modeling analysis.Nature communications · 2023Article
- Can Primary Care Drive Tuberculosis Elimination? Increasing Latent Tuberculosis Infection Testing and Treatment Initiation at a Community Health Center with a Large Non-U.S.-born Population.Journal of immigrant and minority health · 2023Article
- Association between prior tuberculosis disease and dysglycemia within an HIV-endemic, rural South African population.PloS one · 2023Article
- Disparities in years of potential life lost among racial and ethnic groups in Washington state.Archives of public health = Archives belges de sante publique · 2022Article
- A narrative review of tuberculosis in the United States among persons aged 65 years and older.Journal of clinical tuberculosis and other mycobacterial diseases · 2022Review
- Article
- Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae.The Lancet. Global health · 2021Article
- Epidemiology and Prevention of Tuberculosis and Chronic Hepatitis B Virus Infection in the United States.Journal of immigrant and minority health · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Active tuberculosis (TB) disease leads to substantial mortality but is preventable through screening and treatment for latent TB infection. Early mortality after TB diagnosis (≤1 year) is well described, but delayed mortality (>1 year) among patients with active TB is poorly understood. Objective: To compare early and delayed mortality and years of potential life (YPL) lost among patients with active TB disease vs an age-, sex-, and year of diagnosis-matched comparison cohort without active TB disease. Design, Setting, and Participants: This retrospective cohort study, conducted in the integrated health system of Kaiser Permanente Northern California, included patients with microbiologically confirmed active TB disease from January 1, 1997, to December 31, 2017, and a control cohort matched by age, sex, and year of diagnosis. Multivariable models were used to adjust for demographic and clinical characteristics. Patients with active TB disease prior to 1997 were excluded. Data were analyzed from January 1, 2019, to January 31, 2020. Exposure: Microbiologically confirmed TB disease. Main Outcomes and Measures: Early (≤1 year after TB diagnosis) and delayed (>1 year after TB diagnosis) all-cause mortality. Results: A total of 2522 patients who had active TB from 1997 to 2017 were identified, with 17 166 person-years of follow-up. The comparison cohort included 100 880 persons with 735 726 person-years of follow-up. In the active TB and comparison cohorts, similar percentages of persons were male (56.3% vs 55.6%), aged 45 to 64 years (33.7% vs 33.7%), and aged 65 years or older (24.7% vs 24.7%). Both early mortality (7.0%) and delayed mortality (16.3%) were higher among patients with active TB disease compared with those without active TB disease (1.1% and 12.0%, respectively). Patients with active TB disease had a significantly higher risk for early (adjusted hazard ratio [aHR], 7.29; 95% CI, 6.08-8.73) and delayed (aHR, 1.78; 95% CI, 1.61-1.98) mortality compared with the comparison cohort (P < .001). Active TB disease was associated with an adjusted -7.0 (95% CI, -8.4 to -5.5) YPL lost compared with the comparison cohort. Conclusions and Relevance: In this study, patients with active TB disease had significantly higher early and delayed all-cause mortality when adjusting for demographic and clinical characteristics. These findings suggest that TB prevention through screening and treatment of latent TB infection could reduce mortality and YPL lost due to active TB disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.